As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...
Three days ago, on August 4, Amgen ( AMGN) released another strong earnings report. Its revenue was $10.1 billion, up 16.6% ...
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
Amgen (NasdaqGS:AMGN) received a positive opinion from the European Medicines Agency’s CHMP for an expanded Repatha ...
StockStory.org on MSN
Amgen’s Q2 earnings call: Our top 5 analyst questions
Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Healthcare Stocks coverage examines sector conditions, operating developments, competitive dynamics, and broader market ...
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and ...
Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results